Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

PHASE4TerminatedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

April 17, 2014

Primary Completion Date

April 20, 2019

Study Completion Date

June 18, 2019

Conditions
Iron OverloadSickle Cell DiseaseOther Anemias
Interventions
DRUG

Deferiprone

DRUG

Deferoxamine

Trial Locations (33)

19107

Thomas Jefferson University, Philadelphia

29425

Medical University of South Carolina, Charleston

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Children's Hospital of Michigan, Detroit

60612

University of Illinois at Chicago, Chicago

70118

Children's Hospital, New Orleans

80215

King Abdulaziz University Hospital, Jeddah

94609

Children's Hospital Oakland, Oakland

19104-4399

The Children's Hospital of Philadephia, Philadelphia

Unknown

Centro Infantil Boldrini, Campinas

Casa de Saúde Santa Marcelina, São Paulo

Universidade Federal de São Paulo, São Paulo

Hospital for Sick Kids, Toronto

Mansoura University Children's Hospital, Al Mansurah

Alexandria University, Alexandria

Zagazig University, Alexandria

Ains Shams University, Cairo

Cairo University, Cairo

Pediatric Hospital of Cairo University, Cairo

Asser Central Hospital, Abhā

King Khalid University Hospital, Riyadh

National Center for Bone Marrow Transplantation, Tunis

Farhat Hached Hospital, Hematology Department, Sousse

Principal Military Hospital of Instruction of Tunis, Tunis

Cukurova University, Adana

Hacettepe University, Ankara

Istanbul University, Istanbul

Barts and The London, London

Evelina Children's Hospital, London

Imperial College Healthcare NHS Trust, London

90035-903

Hospital de Clínicas de Porto Alegre-HCPA,, Rio Branco

20211-030

Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO, Rio de Janeiro

W12 0HS

Hammersmith Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT02041299 - Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias | Biotech Hunter | Biotech Hunter